PrEP works. Investment in more options must continue.
The development of PrEP products as interventions in HIV prevention represents one of the greatest achievements in the global response to HIV. If combined with community-centered approaches to delivering all HIV prevention options, PrEP products will be instrumental to ending the epidemic. Key to that potential is developing an array of products that can meet the diverse needs of people who need HIV prevention.
The list of now approved products is growing. The list of products in development also needs continued investment so everyone who needs to protect themselves finds a tool that works for them. For an overview of the product registration process, click here.
- Oral PrEP with tenofovir disoproxil and emtricitabine (TDF/FTC)
- Oral PrEP with tenofovir alafenamide and emtricitabine (F/TAF)
- The dapivirine vaginal ring for PrEP (DAP Ring, DVR, or PrEP Ring)
- Injectable cabotegravir for PrEP (Injectable CAB)
Additional strategies in development, including multipurpose prevention products, could protect against HIV, STIs and pregnancy. More primary prevention tools mean more choice, and history shows that more choice increases the use of all products. Learn more about the status of tomorrow’s strategies here.
PrEP doesn’t protect against other STIs or pregnancy. Oral PrEP, the PrEP ring, and injectable PrEP offer protection against HIV. None of these products reduce the risk of chlamydia, gonorrhea, syphilis or herpes, or prevent pregnancy. Male and female condoms do all this. Comprehensive access to all forms of PrEP, condoms, voluntary medical male circumcision (VMMC), communication and counseling must be integrated to empower people around their sexual and reproductive health.
AVAC receives support for PrEPWatch from various sources including the Bill & Melinda Gates Foundation, President’s Emergency Plan for AIDS Relief (PEPFAR) and the United States Agency for International Development (USAID), and the Children’s Investment Fund Foundation. AVAC accepts no money from pharmaceutical companies.